Get the Stockscreener App
55.36
2.50%
1.36
After Hours:
55.36
Akero Therapeutics Inc stock is traded at $55.36, with a volume of 2.26M.
It is up +2.50% in the last 24 hours and up +97.96% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.00
Open:
$55.74
24h Volume:
2.26M
Relative Volume:
2.17
Market Cap:
$3.95B
Revenue:
-
Net Income/Loss:
$-237.22M
P/E Ratio:
-14.65
EPS:
-3.78
Net Cash Flow:
$-212.64M
1W Performance:
+111.58%
1M Performance:
+97.96%
6M Performance:
+108.00%
1Y Performance:
+147.76%
1-Day Range:
$54.66
$57.51
1-Week Range:
$25.69
$58.40
52-Week Range:
$15.32
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
55.36 | 3.95B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Akero stock raised to Buy at Bank of America (AKRO:NASDAQ) - Seeking Alpha
Akero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher After Analyst Upgrade - MarketBeat
Akero Therapeutics shares soar on positive study results - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Akero Therapeutics (NASDAQ:AKRO) Raised to Buy at Bank of America - MarketBeat
Akero Therapeutics senior VP sells $285,150 in stock By Investing.com - Investing.com Australia
Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN
Akero Therapeutics announces proposed public offering of common stock - MSN
Akero Therapeutics senior VP sells $285,150 in stock - Investing.com
Why did Akero (AKRO) stock soar 110% on Monday? - MSN
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock - Investing.com
Akero Therapeutics' chief scientific officer sells $1.74 million in stock By Investing.com - Investing.com UK
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock By Investing.com - Investing.com UK
Jefferies raises Akero Therapeutics price target to $75 - MSN
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study - MSN
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Akero Therapeutic prices upsized stock offering of $350M - MSN
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study - MSN
What is HC Wainwright's Forecast for AKRO FY2029 Earnings? - MarketBeat
Morgan Stanley Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $96.00 - MarketBeat
Akero Therapeutics price target raised to $73 from $56 at Canaccord - MSN
AKRO stock hits 52-week high, soaring to $56.86 - MSN
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Akero's Massive $350M Capital Raise Signals Major Development Push in NASH Treatment - StockTitan
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Canaccord raises Akero Therapeutics target to $73 - MSN
Akero: Reversal Of Cirrhosis With EFX Is A "First" In F4 MASH Patients (NASDAQ:AKRO) - Seeking Alpha
Akero Therapeutics (NASDAQ:AKRO) Given New $96.00 Price Target at Morgan Stanley - MarketBeat
Some Good MASH/NASH News From Akero Therapeutics (AKRO) - Seeking Alpha
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Akero Therapeutics reports breakthrough in MASH cirrhosis study By Investing.com - Investing.com Canada
Akero’s cirrhosis treatment shows promise in Phase IIb study - Yahoo Finance
Akero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Analyst Upgrade - MarketBeat
Akero Therapeutics succeeds with MASH liver treatment at phase 2 - BioPharma-Reporter.com
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday - Benzinga
Citi raises Akero Therapeutics stock target to $80 on EFX data - MSN
Canaccord raises Akero Therapeutics target to $73 By Investing.com - Investing.com Nigeria
Why Akero Therapeutics Inc. (AKRO) Surged on Monday - Insider Monkey
Citigroup Increases Akero Therapeutics (NASDAQ:AKRO) Price Target to $80.00 - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for Akero Therapeutics (NASDAQ:AKRO) Stock - MarketBeat
Akero Thera rockets on positive MASH results - The Pharma Letter
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Akero Shares Skyrocket as MASH Drug Delivers Game-Changing Results - TipRanks
Akero Therapeutics price target raised to $80 from $65 at Citi - TipRanks
Akero (AKRO) Stock Surges on Promising Drug Results - Value the Markets
Akero Therapeutics reports breakthrough in MASH cirrhosis study - MSN
Akero Therapeutics Stock Doubles on Liver Data - MSN
Patience pays off for Akero in MASH - BioCentury
Akero Therapeutics Starts $300 Million Stock Offering -January 27, 2025 at 05:48 pm EST - Marketscreener.com
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):